Abstract Library

#4604 Germline predisposition to neuroendocrine tumours of the pancreas (pNEN) based on mutations in DNA repair genes – BRCA1, BRCA2, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11

Introduction: Neuroendocrine tumours of the pancreas (pNEN) rank as the second most common epithelial neoplasms after pancreatic adenocarcinoma, with increasing prevalence and a mortality rate of 60%. Identifying germline mutations in DNA repair genes such as CHEK2, BRCA1/2, and MUTYH within pNEN cases may pave the way for personalised diagnostics and therapies.

Conference:

Presenting Author:

Authors: Jurecka Lubieniecka B, Ros-Mazurczyuk M, Oczko-Wojciechowska M, Cortez A, Handkiewicz-Junak D,

Keywords: pNEN, DNA repair genes,

#4415 MGMT-activated DUB3 stabilises Nrf2/NCOA4 to modulate apoptosis and ferroptosis, driving temozolomide resistance in pancreatic neuroendocrine tumours

Introduction: O6-methylguanine DNA methyltransferase (MGMT) is a key DNA repair enzyme that removes methyl groups from O(6)-alkylguanine in DNA, introduced by temozolomide (TMZ). Clinical studies in pancreatic neuroendocrine tumours (PanNETs) have confirmed its role in TMZ efficacy.

Conference:

Presenting Author: Cheng Z

Authors: Cheng Z, Yu F, Chen R, Wang Y, Chen X,

Keywords: pancreatic neuroendocrine tumour, MGMT, temozolomide, ferroptosis,

#4397 DNA repair enzyme regulation strategy for enhanced pancreatic neuroendocrine tumour therapy via targeting siRNA-lipid nanoparticles

Introduction: Pancreatic neuroendocrine tumours (panNETs) originate from neuroendocrine cells with high rates of metastasis, rendering many patients’ ineligible for surgical resection. The first-line chemotherapeutic agent temozolomide (TMZ) for metastatic panNETs faces challenges related to resistance, primarily mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).

Conference:

Presenting Author: Wang F

Authors: Wang F, Xu J, Xu X, Qin Y, Chen J,

Keywords: Lipid nanoparticle, siRNA, DNA repair enzyme, pancreatic neuroendocrine tumour, temozolomide,

#4299 Defective DNA repair promotes progression of small intestinal neuroendocrine tumours despite a lack of common genomic drivers

Introduction: The tumorigenesis of small intestinal neuroendocrine tumours (siNETs) is not understood, despite being the most common form of small bowel cancer.

Conference:

Presenting Author: Bolduan F

Authors: Bolduan F, Müller-Bötticher N, Debnath O, Zemojtel T, Kunze C,

Keywords: small intestinal neuroendocrine tumour, pathogenetics, defective DNA repair,

#3371 Utilising DNA-PK inhibitor, M3814, as a radiation sensitizer

Introduction: A novel, clinical-stage DNA-PK inhibitor, M3814, potently and selectively blocks the NHEJ repair pathway for DNA double strand breaks (DSB).

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: DNA-PK inhibitor, M3814, DSB repair, NHEJ, XRT, BON,